Artikel ; Online: Comparative study between topical steroid alone versus combined fractional Erbium:YAG laser with topical steroid in treatment of alopecia areata.
Archives of dermatological research
2022 Band 315, Heft 2, Seite(n) 241–247
Abstract: AA is a common autoimmune skin disease that causes hair loss on the scalp and sometimes other areas of the body. New therapy approaches for alopecia areata are emerging, with the goal of improving clinical outcomes. In this study, the effects of topical ... ...
| Abstract | AA is a common autoimmune skin disease that causes hair loss on the scalp and sometimes other areas of the body. New therapy approaches for alopecia areata are emerging, with the goal of improving clinical outcomes. In this study, the effects of topical steroids against fractional Er:YAG laser followed by topical steroids in the treatment of alopecia areata will be compared. A total of 30 participants with alopecia areata were included in the study. Each patient's lesions were treated with one of two methods: topical clobetasol propionate or fractional Er:YAG laser followed by topical clobetasol propionate. SALT score, patient satisfaction, and dermoscopic imaging were used to evaluate therapeutic response. Both treatment modalities showed a significant clinical improvement in alopecia areata with a statistically significant reduction in the SALT score. The SALT score was more evident in the laser-steroid group. On comparing the dermoscopy findings in both treated areas before and after treatment, a significant reduction was found regarding all dermoscopic findings of alopecia areata in both modalities. Combining fractional Er:YAG laser with topical steroids is found to be a safe treatment modality and more effective than topical steroids in alopecia areata. |
|||||
|---|---|---|---|---|---|---|
| Mesh-Begriff(e) | Humans ; Alopecia Areata/drug therapy ; Alopecia Areata/pathology ; Clobetasol/therapeutic use ; Erbium/therapeutic use ; Lasers, Solid-State/therapeutic use ; Treatment Outcome ; Steroids/therapeutic use | |||||
| Chemische Substanzen | Clobetasol (ADN79D536H) ; Erbium (77B218D3YE) ; Steroids | |||||
| Sprache | Englisch | |||||
| Erscheinungsdatum | 2022-10-20 | |||||
| Erscheinungsland | Germany | |||||
| Dokumenttyp | Journal Article | |||||
| ZDB-ID | 130131-7 | |||||
| ISSN | 1432-069X ; 0340-3696 | |||||
| ISSN (online) | 1432-069X | |||||
| ISSN | 0340-3696 | |||||
| DOI | 10.1007/s00403-022-02417-0 | |||||
| Signatur |
|
|||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Ui VI Zs.10: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.